AbbVie Inc. (NYSE:ABBV) Shares Sold by JB Capital LLC

JB Capital LLC reduced its stake in AbbVie Inc. (NYSE:ABBV) by 2.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,219 shares of the company’s stock after selling 109 shares during the period. JB Capital LLC’s holdings in AbbVie were worth $750,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Princeton Global Asset Management LLC boosted its position in shares of AbbVie by 0.9% during the 4th quarter. Princeton Global Asset Management LLC now owns 29,932 shares of the company’s stock worth $5,319,000 after acquiring an additional 273 shares in the last quarter. Chicago Capital LLC grew its position in shares of AbbVie by 0.6% during the fourth quarter. Chicago Capital LLC now owns 53,003 shares of the company’s stock worth $9,419,000 after acquiring an additional 307 shares during the last quarter. HHM Wealth Advisors LLC increased its stake in AbbVie by 51.2% in the fourth quarter. HHM Wealth Advisors LLC now owns 9,027 shares of the company’s stock valued at $1,604,000 after purchasing an additional 3,058 shares during the period. CFM Wealth Partners LLC raised its holdings in shares of AbbVie by 3.5% in the fourth quarter. CFM Wealth Partners LLC now owns 21,955 shares of the company’s stock valued at $3,901,000 after buying an additional 752 shares during the last quarter. Finally, CENTRAL TRUST Co grew its holdings in shares of AbbVie by 1.4% during the fourth quarter. CENTRAL TRUST Co now owns 232,430 shares of the company’s stock worth $41,303,000 after buying an additional 3,105 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ABBV shares. Citigroup decreased their price target on AbbVie from $215.00 to $205.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. TD Cowen lifted their price target on shares of AbbVie from $195.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, October 7th. BMO Capital Markets lowered their price target on shares of AbbVie from $228.00 to $208.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 12th. Barclays increased their price objective on AbbVie from $200.00 to $212.00 and gave the company an “overweight” rating in a research note on Monday, October 7th. Finally, Daiwa Capital Markets cut shares of AbbVie from an “outperform” rating to a “neutral” rating and set a $180.00 target price for the company. in a research note on Thursday, December 5th. Five investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $205.00.

Insider Transactions at AbbVie

In other AbbVie news, SVP Kevin K. Buckbee sold 1,800 shares of AbbVie stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $172.24, for a total value of $310,032.00. Following the completion of the sale, the senior vice president now directly owns 6,983 shares in the company, valued at $1,202,751.92. The trade was a 20.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.25% of the stock is owned by insiders.

AbbVie Trading Up 4.7 %

Shares of AbbVie stock opened at $183.90 on Monday. The company has a quick ratio of 0.54, a current ratio of 0.65 and a debt-to-equity ratio of 9.64. The firm has a market cap of $324.98 billion, a price-to-earnings ratio of 63.85, a price-to-earnings-growth ratio of 1.77 and a beta of 0.58. AbbVie Inc. has a fifty-two week low of $153.58 and a fifty-two week high of $207.32. The business has a fifty day simple moving average of $176.57 and a 200-day simple moving average of $185.06.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, January 31st. The company reported $2.16 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.82). AbbVie had a net margin of 9.22% and a return on equity of 244.01%. During the same quarter last year, the business posted $2.79 EPS. On average, equities analysts forecast that AbbVie Inc. will post 10.09 EPS for the current fiscal year.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.